Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.
Here's a review of the key highlights from the company's big announcement:
First, Novavax said that its phase 3 Prepare trial -- which is studying its respiratory syncytial virus candidate, RSV F Vaccine, in infants via maternal immunization -- continues to progress. The company said that it is actively enrolling patients at 80 sites in 11 countries.
Source: Fool.com
Novavax Inc. Stock
€6.87
1.930%
Currently there is a rather positive sentiment for Novavax Inc. with 8 Buy predictions and 3 Sell predictions.
As a result the target price of 11 € shows a very positive potential of 60.12% compared to the current price of 6.87 € for Novavax Inc..
